Seres Therapeutics, Inc.
MCRBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSeres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company carries a $21.0M market cap, placing it firmly in the micro-cap category. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Market Cap
$21.0M
Beta
0.31
P/E (TTM)
—
P/E (Fwd)
-0.42
EPS (TTM)
$-2.42
EPS (Fwd)
$-4.95
ROE
-66.6%
ROA
-39.9%
Cash
$15.6M
Total Debt
$56.6M
Free CF
-$64.6M
52W Change
-87.8%
Annual Financials
Cash vs Debt
Where MCRB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MCRB finished 60.84% below its 150-day moving average ($6.18) and 68.65% below its 200-day moving average ($7.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MCRB overbought or oversold?
At the October 20, 2026 close, MCRB's RSI(14) was 16.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Seres Therapeutics, Inc. carries $56.6M in total debt against $15.6M in cash reserves — debt is roughly 3.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$64.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -66.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Seres Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MCRB.